Paris, France and Camberley, UK – 25 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the notification on 20 March 2020, the Company has signed an agreement for certain contract manufacturing services with Yourgene Health Plc (“Yourgene”) (AIM: YGEN), an international molecular diagnostics group.
Visit PageCategory: NOVAPREP®
US FDA Emergency Use Authorization for COVID-19 diagnostic test COVID-19 RUO test receives approval in Indonesia
Paris, France and Camberley, UK – 23 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that the US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its COVID-19 test. As a result, hospitals and laboratories in the US will
Visit PageMise à jour sur le test pour le coronavirus Augmentation significative de la demande Poursuite de l’expansion des capacités de production
Paris, France et Camberley, Royaume-Uni – 20 mars 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir de faire le point sur le nouveau test de détection du coronavirus (COVID-19) mis au point par Primerdesign, sa division de diagnostic moléculaire basée au Royaume-Uni. http://novacyt.com/wp-content/uploads/2020/03/Novacyt-mise-à-jour-sur-le-test-pour-le-coronavirus-FRENCH-20.03.20.pdf
Visit Page